In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Australia Clears Novartis Buy Of Alcon Without Key Eye-care Line

This article was originally published in PharmAsia News

Executive Summary

Australian authorities have given their permission for the merger of Switzerland's Novartis AG and Alcon Laboratories, based in the United States, but incorporated in Switzerland

You may also be interested in...



Tweak API Scheme For ‘Self-Reliant’ India, Says Industry

Companies including Dr Reddy’s will consider investing in new API units if the Indian government tweaks its incentive scheme to permit exports of surplus production. Other suggested changes to the $1.3bn stimulus, aimed at enhancing the country's medicines security, include extending incentives to brownfield expansions and removing restrictions on a change in product mix.

The Global Generics & Biosimilars Awards 2020 Is Going Digital

The Global Generics & Biosimilars Awards 2020 will take place on 3 November as a digital event, with a newly-extended entry deadline date of 14 August.

Coronavirus Update: Japan's Supercomputer Joins COVID-19 Drug Hunt

Developed by Japan’s national research institute, the supercomputer has been tasked with characterizing the SARS-CoV-2 virus, identifying therapeutic molecules, modeling infection spread and socio-economic impact.

UsernamePublicRestriction

Register

SC142523

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel